XKH009
XKH009 is a bispecific antibody drug independently developed by Kanova Biopharma, targeting PD-1and B7H3. XKH009 can connect immune cells (such as T or NK cells) with tumor/APC cells, and by simultaneously blocking two immune suppressive signaling pathways mediated by PD-1 and B7H3, it restores the immune effect of T and NK cells and their inhibitory effect tumors. Animal models of tumors have shown that bispecific antibodies against PD-1 and B7H3 have better anti-tumor effect than PD-1 or B7H3 monoclonal antibodies.
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com